Available Technology

Zirconium-89 PET Imaging Agent for Cancer

The technology is tetrahydroxamate chelation technology that provides a stable Zr-89 chelated immuno-PET imaging agent for cancer that reduces the amounts of Zr-89 that is released from the current state of the art chemistry and agent, desferrioxamine B (DFB), that is currently in clinical use. The tetrahydroxamates in either a linear or macrocyclic form exhibit greater stability as chelating agents for Zr-89 as compared to the currently in use siderophore DFB, a trihydroxamate. In imaging agents currently in clinical development, Zr-89 leaks from the DFB chelate which results in radioisotope accumulation in the bone 2-3 days after injection that increases over time. Upon in vitro examination, the tetrahydroxamate chelated Zr-89 remained kinetically inert at 7 or more days while that formed from DFB demonstrated instability.

Patent Abstract: 

The technology is tetrahydroxamate chelation technology that provides a stable Zr-89 chelated immuno-PET imaging agent for cancer that reduces the amounts of Zr-89 that is released from the current state of the art chemistry and agent, desferrioxamine B (DFB), that is currently in clinical use. The tetrahydroxamates in either a linear or macrocyclic form exhibit greater stability as chelating agents for Zr-89 as compared to the currently in use siderophore DFB, a trihydroxamate. In imaging agents currently in clinical development, Zr-89 leaks from the DFB chelate which results in radioisotope accumulation in the bone 2-3 days after injection that increases over time. Upon in vitro examination, the tetrahydroxamate chelated Zr-89 remained kinetically inert at 7 or more days while that formed from DFB demonstrated instability.

Benefits 
High stability -Low toxicity
Inventors: 

Martin Brechbiel

Patent Number: 
14774,831 US Application No. 61779,016 PCT Appli
Lab Representatives
Share to Facebook Share to Twitter Share to Google Plus Share to Linkedin